Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
As the next installment of the podcast series from the GRACE NSCLC Patient Education Forum, I'm pleased to offer a presentation by the Chief of the Thoracic Oncology Division at Swedish Medical Center in Seattle -- my own institution. Dr. Aye has been at the center of the program from the beginning, and whatever success our center has achieved in the field is a reflection on his steady leadership. He was one of the leading reasons I felt I would be happy at Swedish, and nearly seven years later, I can say that he's been one of my favorite aspects of working there. Not every lung cancer program is as collegial and collaborative in its multi-disciplinary approach.
He's also a terrific surgeon, and his talk is on the general principles of surgery for early stage NSCLC. Here's links to the video and audio only versions of his presentation, as well as the transcript and figures.
[powerpress]
dr-aye-surgery-for-nsclc-transcript
dr-aye-surgery-for-nsclc-figures
Dr. Aye Surgery for NSCLC Audio Program
I hope you find it helpful.
Please feel free to offer comments and raise questions in our
discussion forums.
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: